A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer
- 1 July 2015
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 92 (4) , 856-862
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 yearsRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experienceRadiation Oncology, 2013
- Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic reviewBMC Cancer, 2012
- Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate CancerJournal of Clinical Oncology, 2011
- Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesRadiation Oncology, 2011
- Detecting Disabilities in Older Patients With Cancer: Comparison Between Comprehensive Geriatric Assessment and Vulnerable Elders Survey-13Journal of Clinical Oncology, 2010
- Hypofractionation for Prostate CancerThe Cancer Journal, 2009
- Psychometric properties of a prostate cancer radiation late toxicity questionnaireHealth and Quality of Life Outcomes, 2007
- A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationCancer, 2007